<DOC>
	<DOCNO>NCT02328716</DOCNO>
	<brief_summary>The purpose clinical trial Investigate whether administration HIPEC Cisplatin ( 75 milligram per square meter body surface ) surgical cytoreduction woman ovarian , tubal primary peritoneal carcinoma increase disease-free survival period compare patient without HIPEC treatment .</brief_summary>
	<brief_title>Cytoreduction With Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy ( HIPEC ) Patients With Peritoneal Carcinomatosis From Ovarian Cancer , Fallopian Tube Primary Peritoneal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Peritoneal carcinomatosis arise ovarian epithelial carcinoma ( stage III high ) , carcinoma fallopian tube primary peritoneal carcinoma . Residual tumor &lt; 2.5 mm completion cytoreductive surgery . Aged &lt; 75 year . Baseline ECOG 01 ( Eastern Cooperative Oncologic Group ) . Adequate bone marrow function hemoglobin ? 8 g/dl ( correction iron deficiency anemia ) , white blood cell count ? 3,000/mm3 , platelet ? 100,000/mm3 . Adequate renal function creatinine ? 1.5 mg/ dl . Adequate liver function bilirubin level ? 1.5 mg / dl AST ALT ? 80 IU / L. Optimal cardiopulmonary function . In recurrence , diseasefree interval &gt; 6 month . Voluntary sign write informed consent . Extraperitoneal tumor disease . Suboptimal debulking ( residual tumor &gt; 2.5 mm ) . Previous history malignancy ( exclude skin ) Intestinal obstruction time evaluation . Renal failure . Heart failure . Uncontrolled infection . Pregnant lactating patient . In recurrence , diseasefree interval &lt; 6 month .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>